Neurodevelopmental Outcomes at Age 5 Years After Prophylactic Early High-Dose Recombinant Human Erythropoietin for Neuroprotection in Very Preterm Infants

Giancarlo Natalucci; Bea Latal; Brigitte Koller; Christoph Rüegger; Beate Sick; Leonhard Held; Jean-Claude Fauchère; Swiss EPO Neuroprotection Trial Group

doi:10.1001/jama.2020.19395

Neurodevelopmental Outcomes at Age 5 Years After Prophylactic Early High-Dose Recombinant Human Erythropoietin for Neuroprotection in Very Preterm Infants

JAMA. 2020 Dec 8;324(22):2324-2327. doi: 10.1001/jama.2020.19395.

Authors

Giancarlo Natalucci¹, Bea Latal², Brigitte Koller¹, Christoph Rüegger¹, Beate Sick³, Leonhard Held³, Jean-Claude Fauchère¹; Swiss EPO Neuroprotection Trial Group

Affiliations

¹ Department of Neonatology, University Hospital Zurich, Zurich, Switzerland.
² Child Development Center, University Children's Hospital Zurich, Zurich, Switzerland.
³ Epidemiology, Biostatistics, and Prevention Institute (EBPI), University of Zurich, Zurich, Switzerland.

Abstract

This study reports 5-year neurodevelopmental outcomes for Swiss children born before 32 weeks’ gestation and randomized at birth to receive early high-dose recombinant human erythropoietin (rhEpo) vs placebo.

Publication types

Clinical Trial, Phase III
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Child Development / drug effects
Child, Preschool
Developmental Disabilities / prevention & control
Double-Blind Method
Erythropoietin / therapeutic use*
Follow-Up Studies
Humans
Infant, Newborn
Infant, Premature* / growth & development
Infant, Premature* / psychology
Neurodevelopmental Disorders / prevention & control*
Neuroprotective Agents / therapeutic use*
Treatment Outcome

Substances

Neuroprotective Agents
Erythropoietin